UNSPSC 51402204: Duloxetine

This classification denotes an antidepressant agent with the molecular formula C18H19NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O5TNM5N07U, chemically known as 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one but generally known as duloxetine, which bears US NIH Compound Identifier 3151. European Medicines Agency schedules Duloxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06424MIG.

UNSPSC 51402204 Duloxetine is a Commodity code that designates a specific antidepressant pharmaceutical active ingredient, yet the recent state and local solicitations tagged under this code do not reflect duloxetine procurement at all. Instead, they show purchasing activity for naloxone (an opioid antagonist), multi-source generic pharmaceuticals and OTC products through cooperative purchasing arrangements, and exploratory direct-to-manufacturer prescription programs. The mismatch suggests either a data-tagging error in the state and local procurement systems or a misalignment between the UNSPSC taxonomy and the actual buying patterns in these jurisdictions. When recent opportunities are examined on their merits, they reflect broader pharmaceutical supply and dispensing initiatives rather than duloxetine-specific sourcing.

The issuing bodies include a county health department (Seminole County, Florida), a state HHS agency (Texas Health and Human Services Commission), and a multistate cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance, with participating members including Oregon). Representative recent activity includes Seminole County's IFB for naloxone and drug deactivation systems posted June 30, 2026 with a July 26, 2023 response date, Texas HHS's Request for Information on direct-to-manufacturer prescription programs issued April 3, 2026, and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products posted January 20, 2026 with a March 26, 2026 response deadline. Geographic coverage spans Florida, Texas, and the upper Midwest through cooperative purchasing. The code shows little relevant recent activity aligned with duloxetine as a discrete product line; pursuit under this specific code is not supported by current solicitation evidence.